We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
Read MoreHide Full Article
Haemonetics Corporation (HAE - Free Report) has been on a healthy growth trajectory of late. Shares of the company have soared 66.2% in the last six months, ahead of the S&P 500 index’s 11% gain. The stock has a market cap of $3.70 billion.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has returned 84.5%, compared with the S&P 500 index’s gain of 14.7%. This value is also higher than the broader industry’s 13% rally.
In view of the above positives, one may expect the company to scale new highs in the upcoming quarters as well. Further, the stock delivered an average positive earnings surprise of 17.5% in the trailing four quarters. A positive growth rate of 14.2% for the next year also instils investors’ optimism in the stock.
Moreover, estimate revision trends for current-year earnings look impressive. For the stock has seen the Zacks Consensus Estimate being moved north five times over the last 60 days with no downward revision witnessed.
Factors Driving Haemonetics
Let’s take a look at the possible growth propellers:
Surging Segmental Revenues: Last quarter, Plasma revenues for this Massachusetts-based blood management company were up 4% on a year-over-year basis. The upside was driven by a strong performance in disposables and software, particularly in the United States. Additionally, Hospital Business revenues grew 6% on the back of consistent results in North America as well as improved international results in the key markets.
Expanding Margins: Last quarter, gross margin expanded 310 basis points (bps) to 47.6% on a year-over-year basis. Meanwhile, operating margin improved 270 bps to 17.9% year over year.
NexSys PCS: Market seems to be upbeat about Haemonetics’ recently-introduced new platform, NexSys Plasma Collection System (PCS). The device is designed to increase overall plasma yield per donor through planned embedded software upgrades.
Notably, the device has also recently received an FDA clearance with a CE Mark expected come spring. Moreover, management expects a 510 (k) submission for the embedded software and firmware via which, the NexSys PCS functions.
EPS Guidance Raised: Haemonetics increased 2018 guidance for earnings estimated the metric in the range of $1.80-$1.90 per share compared with the previous projection of $1.65-$1.75. This upped view is indicative of the continuation of the overall bullish sentiment surrounding the stock.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Centene Corporation (CNC - Free Report) , BIOVERATIV INC and athenahealth, Inc. , each sporting the same solid Zacks Rank of 1 as Haemonetics. You can see the complete list of today’s Zacks #1 Rank stocks here.
Centene’s projected long-term growth rate is 14.4%. The stock has returned 16.9% in the past six months.
BIOVERATIV has an expected long-term growth rate of 14%. The stock has skyrocketed a whopping 106.8% in the past three months.
athenahealth has a positive expected long-term growth rate of 20.7%. The stock has gained 5.1% in the past three months.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
Haemonetics Corporation (HAE - Free Report) has been on a healthy growth trajectory of late. Shares of the company have soared 66.2% in the last six months, ahead of the S&P 500 index’s 11% gain. The stock has a market cap of $3.70 billion.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has returned 84.5%, compared with the S&P 500 index’s gain of 14.7%. This value is also higher than the broader industry’s 13% rally.
In view of the above positives, one may expect the company to scale new highs in the upcoming quarters as well. Further, the stock delivered an average positive earnings surprise of 17.5% in the trailing four quarters. A positive growth rate of 14.2% for the next year also instils investors’ optimism in the stock.
Moreover, estimate revision trends for current-year earnings look impressive. For the stock has seen the Zacks Consensus Estimate being moved north five times over the last 60 days with no downward revision witnessed.
Factors Driving Haemonetics
Let’s take a look at the possible growth propellers:
Surging Segmental Revenues: Last quarter, Plasma revenues for this Massachusetts-based blood management company were up 4% on a year-over-year basis. The upside was driven by a strong performance in disposables and software, particularly in the United States. Additionally, Hospital Business revenues grew 6% on the back of consistent results in North America as well as improved international results in the key markets.
Expanding Margins: Last quarter, gross margin expanded 310 basis points (bps) to 47.6% on a year-over-year basis. Meanwhile, operating margin improved 270 bps to 17.9% year over year.
NexSys PCS: Market seems to be upbeat about Haemonetics’ recently-introduced new platform, NexSys Plasma Collection System (PCS). The device is designed to increase overall plasma yield per donor through planned embedded software upgrades.
Notably, the device has also recently received an FDA clearance with a CE Mark expected come spring. Moreover, management expects a 510 (k) submission for the embedded software and firmware via which, the NexSys PCS functions.
EPS Guidance Raised: Haemonetics increased 2018 guidance for earnings estimated the metric in the range of $1.80-$1.90 per share compared with the previous projection of $1.65-$1.75. This upped view is indicative of the continuation of the overall bullish sentiment surrounding the stock.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Centene Corporation (CNC - Free Report) , BIOVERATIV INC and athenahealth, Inc. , each sporting the same solid Zacks Rank of 1 as Haemonetics. You can see the complete list of today’s Zacks #1 Rank stocks here.
Centene’s projected long-term growth rate is 14.4%. The stock has returned 16.9% in the past six months.
BIOVERATIV has an expected long-term growth rate of 14%. The stock has skyrocketed a whopping 106.8% in the past three months.
athenahealth has a positive expected long-term growth rate of 20.7%. The stock has gained 5.1% in the past three months.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>